In a legal twist, Novo Nordisk seeks to block Eli Lilly’s advertisements for obesity and diabetes drugs in the U.S. Novo argues the ads mislead consumers by comparing outdated studies, warranting a preliminary injunction to prevent misinformation.
Eli Lilly stands by its advertising practices, rejecting claims of misinformation. As both pharmaceutical giants vie for dominance in the booming obesity drug market, expected to exceed $100 billion by decade’s end, Novo accuses Lilly’s ads of giving a false impression.
Novo’s lawsuit highlights unfair competition and false advertising, demanding Eli Lilly withdraw its campaigns and issue corrective ads. The case underscores Novo’s determination to aggressively manage its business and public perception. Analyst Evan Seigerman notes Novo’s sharpened competitive strategy.
(With inputs from agencies.)